|
|
- Introduction
- Global Markets Direct Report Coverage
- Dyspepsia Overview
- Therapeutics Development
- An Overview of Pipeline Products for Dyspepsia
- Dyspepsia Therapeutics under Development by Companies
- Dyspepsia Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Dyspepsia Therapeutics – Products under Development by Companies
- Dyspepsia Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Dyspepsia Therapeutics Development
- GlaxoSmithKline plc
- Dong-A Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Zeria Pharmaceutical Co Ltd
- ARYx Therapeutics
- Rottapharm SpA
- Rose Pharma A/S
- RaQualia Pharma Inc.
- Dyspepsia – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Z-338 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Z-338 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GSK962040 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ATI-7505 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Aciphex Extended Release - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- CR 2017 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DA-6650 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RQ-00201894 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- DA-9701 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Amitriptyline - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Rabeprazole - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Rebamipide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Imipramine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Cinitapride - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AJA777 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Escitalopram - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Dyspepsia Therapeutics – Drug Profile Updates
- Dyspepsia Therapeutics – Discontinued Products
- Dyspepsia Therapeutics - Dormant Products
- Dyspepsia – Product Development Milestones
- Featured News & Press Releases
- Sep 29, 2010: Zeria And Astellas Pharma Submit NDA Of Z-338 /YM443 For Functional Dyspepsia In Japan
- Jun 28, 2010: Zeria Announces Positive Phase III Trial Results Of Z-338 In Dyspepsia
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Dyspepsia, H1 2012
- Products under Development for Dyspepsia – Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- GlaxoSmithKline plc, H1 2012
- Dong-A Pharmaceutical Co., Ltd., H1 2012
- Eisai Co., Ltd., H1 2012
- Zeria Pharmaceutical Co Ltd, H1 2012
- ARYx Therapeutics, H1 2012
- Rottapharm SpA, H1 2012
- Rose Pharma A/S, H1 2012
- RaQualia Pharma Inc., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
- Dyspepsia Therapeutics – Drug Profile Updates
- Dyspepsia Therapeutics – Discontinued Products
- Dyspepsia Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Dyspepsia, H1 2012
- Products under Development for Dyspepsia – Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Gastrointestinal Reports